PDUFA Public Forum Previews Hill Debate; Safety, Critical Path Emphasized
Executive Summary
With the Prescription Drug User Fee Act moving towards reauthorization, a public forum on Feb. 16 hinted at how that debate may play out on Capitol Hill. At the meeting sponsored by FDA, outside groups voiced concerns about the agency's proposal for the PDUFA program and made their case for how FDA should organize and spend requested funding
You may also be interested in...
PDUFA Negotiations Would Add Patient, Consumer Reps Under House Bill
The role of drug manufacturers in negotiating how FDA spends prescription drug user fees would be diminished under a draft user fee reauthorization bill prepared for markup in the House Energy and Commerce Committee's Health Subcommittee
PDUFA Negotiations Would Add Patient, Consumer Reps Under House Bill
The role of drug manufacturers in negotiating how FDA spends prescription drug user fees would be diminished under a draft user fee reauthorization bill prepared for markup in the House Energy and Commerce Committee's Health Subcommittee
DTC Review Will Cost Industry $83,000 Per Ad Under FDA’s Final PDUFA Plan
FDA expects to charge companies $83,000 per advertisement under a pre-review program included as part of the agency's proposal for renewal of the prescription drug user fee program